Biodistribution and radiation dosimetry of the 18 kDa translocator protein (TSPO) radioligand [ 18F]FEDAA1106: A human whole-body PET study (623 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2011 Nov; 38(11): 2058-2065.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 4.991, 5-year impact factor: 4.756
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-80255132720&partnerID=40&md5=687f3b08e33f326422b4f968325a0153
Keywords: [ 18f]fedaa1106, Dosimetry, Translocator Protein, 18 Kda Translocator Protein, Fedaa 1106, Fluorine 18, Radioligand, Radiopharmaceutical Agent, Transcription Factor, Unclassified Drug, Adult, Article, Bladder, Brain, Clinical Assessment, Controlled Study, Dose Response, Drug Distribution, Female, Heart, Human, Human Experiment, Kidney, Liver, Normal Human, Radiation Detection, Radiation Dose, Salivary Gland, Small Intestine, Spleen, Stomach, Thyroid Gland, Time Series Analysis, Whole Body Pet, Acetamides, Positron-Emission Tomography, Radiation Dosage, Radiometry, Receptors, Whole Body Imaging, [18f] Fedaa1106,
Affiliations:
*** IBB - CNR ***
Department of Clinical Neuroscience, Psychiatry Section, Karolinska Institutet, Stockholm 171 76, Sweden
Department of Nuclear Medicine, Karolinska Institutet, Stockholm, Sweden
CDE Dosimetry Services, Inc., Knoxville, TN, United States
Karolinska Trial Alliance, Karolinska University Hospital, Stockholm, Sweden
Bayer Schering Pharma AG, Berlin, Germany
References:
Not available.
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2011 Nov; 38(11): 2058-2065.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 4.991, 5-year impact factor: 4.756
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-80255132720&partnerID=40&md5=687f3b08e33f326422b4f968325a0153
Keywords: [ 18f]fedaa1106, Dosimetry, Translocator Protein, 18 Kda Translocator Protein, Fedaa 1106, Fluorine 18, Radioligand, Radiopharmaceutical Agent, Transcription Factor, Unclassified Drug, Adult, Article, Bladder, Brain, Clinical Assessment, Controlled Study, Dose Response, Drug Distribution, Female, Heart, Human, Human Experiment, Kidney, Liver, Normal Human, Radiation Detection, Radiation Dose, Salivary Gland, Small Intestine, Spleen, Stomach, Thyroid Gland, Time Series Analysis, Whole Body Pet, Acetamides, Positron-Emission Tomography, Radiation Dosage, Radiometry, Receptors, Whole Body Imaging, [18f] Fedaa1106,
Affiliations:
*** IBB - CNR ***
Department of Clinical Neuroscience, Psychiatry Section, Karolinska Institutet, Stockholm 171 76, Sweden
Department of Nuclear Medicine, Karolinska Institutet, Stockholm, Sweden
CDE Dosimetry Services, Inc., Knoxville, TN, United States
Karolinska Trial Alliance, Karolinska University Hospital, Stockholm, Sweden
Bayer Schering Pharma AG, Berlin, Germany
References:
Not available.
Biodistribution and radiation dosimetry of the 18 kDa translocator protein (TSPO) radioligand [ 18F]FEDAA1106: A human whole-body PET study
Purpose: [ 18F]FEDAA1106 is a recently developed positron emission tomography (PET) radioligand for in vivo quantification of the 18 kDa translocator protein [TSPO or, as earlier called, the peripheral benzodiazepine receptor (PBR)]. TSPO imaging is expected to be useful for the clinical evaluation of neuroinflammatory diseases. The aim of this study was to provide dosimetry estimates for [ 18F]FEDAA1106 based on human whole-body PET measurements. Methods: PET scans were performed for a total of 6.6 h after the injection of 183.8 ± 9.1 MBq of [ 18F]FEDAA1106 in six healthy subjects. Regions of interest were drawn on coronal images. Estimates of the absorbed doses of radiation were calculated using the OLINDA software. Results: Peak uptake was largest in lungs, followed by liver, small intestine, kidney, spleen and other organs. Peak values of the percent injected dose (%ID) at a time after radioligand injection were calculated for the lungs (27.1%ID at 0.2 h), liver (21.1%ID at 0.6 h), small intestine (10.4%ID at 6.3 h), kidney (4.9%ID at 1.8 h) and spleen (4.6%ID at 0.6 h). The largest absorbed dose was found in the spleen (0.12 mSv/MBq), followed by kidneys (0.094 mSv/MBq). The calculated mean effective dose was 0.036 mSv/MBq. Conclusion: Based on the distribution and dose estimates, the estimated radiation burden of [ 18F]FEDAA1106 is moderately higher than that of [ 18F]fluorodeoxyglucose (FDG). In clinical studies, the administered activity of this radioligand ought to be adjusted in line with regional regulations. This result would be helpful for further clinical TSPO imaging studies. © 2011 Springer-Verlag.
Purpose: [ 18F]FEDAA1106 is a recently developed positron emission tomography (PET) radioligand for in vivo quantification of the 18 kDa translocator protein [TSPO or, as earlier called, the peripheral benzodiazepine receptor (PBR)]. TSPO imaging is expected to be useful for the clinical evaluation of neuroinflammatory diseases. The aim of this study was to provide dosimetry estimates for [ 18F]FEDAA1106 based on human whole-body PET measurements. Methods: PET scans were performed for a total of 6.6 h after the injection of 183.8 ± 9.1 MBq of [ 18F]FEDAA1106 in six healthy subjects. Regions of interest were drawn on coronal images. Estimates of the absorbed doses of radiation were calculated using the OLINDA software. Results: Peak uptake was largest in lungs, followed by liver, small intestine, kidney, spleen and other organs. Peak values of the percent injected dose (%ID) at a time after radioligand injection were calculated for the lungs (27.1%ID at 0.2 h), liver (21.1%ID at 0.6 h), small intestine (10.4%ID at 6.3 h), kidney (4.9%ID at 1.8 h) and spleen (4.6%ID at 0.6 h). The largest absorbed dose was found in the spleen (0.12 mSv/MBq), followed by kidneys (0.094 mSv/MBq). The calculated mean effective dose was 0.036 mSv/MBq. Conclusion: Based on the distribution and dose estimates, the estimated radiation burden of [ 18F]FEDAA1106 is moderately higher than that of [ 18F]fluorodeoxyglucose (FDG). In clinical studies, the administered activity of this radioligand ought to be adjusted in line with regional regulations. This result would be helpful for further clinical TSPO imaging studies. © 2011 Springer-Verlag.
Biodistribution and radiation dosimetry of the 18 kDa translocator protein (TSPO) radioligand [ 18F]FEDAA1106: A human whole-body PET study
No results. |
Biodistribution and radiation dosimetry of the 18 kDa translocator protein (TSPO) radioligand [ 18F]FEDAA1106: A human whole-body PET study
Other filter: ([btitle,keywords] "[ 18f]fedaa1106" OR ...
Gargiulo S, Anzilotti S, Coda AR, Gramanzini M, Greco A, Panico M, Vinciguerra A, Zannetti A, Vicidomini C, Dolle F, Pignataro G, Quarantelli M, Annunziato L, Brunetti A, Salvatore M, Pappata S
* Imaging of brain TSPO expression in a mouse model of amyotrophic lateral sclerosis with (18)F-DPA-714 and micro-PET/CT (1256 views) (PDF 353 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 1619-7070print), 2016 Jan 27; 43(7): 1348-1359.
Impact Factor: 7.277
View Export to BibTeX Export to EndNote
Vicidomini C, Panico M, Greco A, Gargiulo S, Coda ARD, Zannetti A, Gramanzini M, Roviello GN, Quarantelli M, Alfano B, Tavitian B, Dolle F, Salvatore M, Brunetti A, Pappata S
* In vivo imaging and characterization of [(18)F]DPA-714, a potential new TSPO ligand, in mouse brain and peripheral tissues using small-animal PET (1212 views) (PDF 328 views)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897, 0969-8051linking), 2015 Mar; 42(3): 309-316.
Impact Factor: 2.429
View Export to BibTeX Export to EndNote
Storto G, Gallicchio R, Pellegrino T, Nardelli A, Capacchione D, Sirignano C, Pace L
* Impact of F-18-fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP (677 views) (PDF 69 views)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897, 0969-8051linking), 2013 May; 40(4): 518-523.
Impact Factor: 2.408
View Export to BibTeX Export to EndNote
Gulyas B, Vas A, Toth M, Takano A, Varrone A, Cselenyi Z, Schain M, Mattsson P, Halldin C
* Age and disease related changes in the translocator protein (TSPO) system in the human brain: Positron emission tomography measurements with [11C]vinpocetine (807 views)
Neuroimage (ISSN: 1053-8119, 1053-8119linking), 2011 Jun 1; 56(3): 1111-1121.
Impact Factor: 5.895
View Export to BibTeX Export to EndNote
Zannetti A, Del Vecchio S, Iommelli F, Del Gatto A, De Luca S, Zaccaro L, Papaccioli A, Sommella J, Panico M, Speranza A, Grieco P, Novellino E, Saviano M, Pedone C, Salvatore M
* Imaging of αvβ3 expression by a bifunctional chimeric RGD peptide not cross-reacting with α vβ5 (1324 views)
Clin Cancer Res (ISSN: 1078-0432, 1078-0432linking, 1078-0432print), 2009 Sep 15; 15(16): 5224-5233.
Impact Factor: 6.747
View Export to BibTeX Export to EndNote
Takano A, Varrone A, Gulyas B, Karlsson P, Tauscher J, Halldin C
* Mapping of the norepinephrine transporter in man using PET with (S, S)-[F-18]FMeNER-D-2 (665 views) (PDF 255 views)
Neuroimage (ISSN: 1053-8119, 1053-8119linking), 2008 Sep 15; 41: 474-482.
Impact Factor: 5.694
View Export to BibTeX Export to EndNote
Vander Borght T, Asenbaum S, Bartenstein P, Halldin C, Kapucu O, Van Laere K, Varrone A, Tatsch K
* EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues (948 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006 Nov; 33(11): 1374-1380.
Impact Factor: 4.041
View Export to BibTeX Export to EndNote
Zingone A, Seidel J, Aloj L, Caraco C, Vaquero JJ, Jagoda EM, Chou JY, Green MV, Eckelman WC
* Monitoring the correction of glycogen storage disease type 1a in a mouse model using [18F]FDG and a dedicated animal scanner (493 views)
Life Sci (ISSN: 0024-3205), 2002; 71(11): 1293-1301.
Impact Factor: 1.824
View Export to BibTeX Export to EndNote
Wang H, Maurea S, Mainolfi C, Fiore F, Gravina A, Panico M, Bazzicalupo L, Salvatore M
Tc-99m MIBI scintigraphy in patients with lung cancer comparison with CT and fluorine-18 FDG PET imaging (623 views)
Clin Nucl Med (ISSN: 0363-9762, 1536-0229, 1536-0229electronic), 1997 Apr; 22(4): 243-249.
Impact Factor: 0.34
View Export to BibTeX Export to EndNote
* Imaging of brain TSPO expression in a mouse model of amyotrophic lateral sclerosis with (18)F-DPA-714 and micro-PET/CT (1256 views) (PDF 353 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 1619-7070print), 2016 Jan 27; 43(7): 1348-1359.
Impact Factor: 7.277
View Export to BibTeX Export to EndNote
Vicidomini C, Panico M, Greco A, Gargiulo S, Coda ARD, Zannetti A, Gramanzini M, Roviello GN, Quarantelli M, Alfano B, Tavitian B, Dolle F, Salvatore M, Brunetti A, Pappata S
* In vivo imaging and characterization of [(18)F]DPA-714, a potential new TSPO ligand, in mouse brain and peripheral tissues using small-animal PET (1212 views) (PDF 328 views)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897, 0969-8051linking), 2015 Mar; 42(3): 309-316.
Impact Factor: 2.429
View Export to BibTeX Export to EndNote
Storto G, Gallicchio R, Pellegrino T, Nardelli A, Capacchione D, Sirignano C, Pace L
* Impact of F-18-fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP (677 views) (PDF 69 views)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897, 0969-8051linking), 2013 May; 40(4): 518-523.
Impact Factor: 2.408
View Export to BibTeX Export to EndNote
Gulyas B, Vas A, Toth M, Takano A, Varrone A, Cselenyi Z, Schain M, Mattsson P, Halldin C
* Age and disease related changes in the translocator protein (TSPO) system in the human brain: Positron emission tomography measurements with [11C]vinpocetine (807 views)
Neuroimage (ISSN: 1053-8119, 1053-8119linking), 2011 Jun 1; 56(3): 1111-1121.
Impact Factor: 5.895
View Export to BibTeX Export to EndNote
Zannetti A, Del Vecchio S, Iommelli F, Del Gatto A, De Luca S, Zaccaro L, Papaccioli A, Sommella J, Panico M, Speranza A, Grieco P, Novellino E, Saviano M, Pedone C, Salvatore M
* Imaging of αvβ3 expression by a bifunctional chimeric RGD peptide not cross-reacting with α vβ5 (1324 views)
Clin Cancer Res (ISSN: 1078-0432, 1078-0432linking, 1078-0432print), 2009 Sep 15; 15(16): 5224-5233.
Impact Factor: 6.747
View Export to BibTeX Export to EndNote
Takano A, Varrone A, Gulyas B, Karlsson P, Tauscher J, Halldin C
* Mapping of the norepinephrine transporter in man using PET with (S, S)-[F-18]FMeNER-D-2 (665 views) (PDF 255 views)
Neuroimage (ISSN: 1053-8119, 1053-8119linking), 2008 Sep 15; 41: 474-482.
Impact Factor: 5.694
View Export to BibTeX Export to EndNote
Vander Borght T, Asenbaum S, Bartenstein P, Halldin C, Kapucu O, Van Laere K, Varrone A, Tatsch K
* EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues (948 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006 Nov; 33(11): 1374-1380.
Impact Factor: 4.041
View Export to BibTeX Export to EndNote
Zingone A, Seidel J, Aloj L, Caraco C, Vaquero JJ, Jagoda EM, Chou JY, Green MV, Eckelman WC
* Monitoring the correction of glycogen storage disease type 1a in a mouse model using [18F]FDG and a dedicated animal scanner (493 views)
Life Sci (ISSN: 0024-3205), 2002; 71(11): 1293-1301.
Impact Factor: 1.824
View Export to BibTeX Export to EndNote
Wang H, Maurea S, Mainolfi C, Fiore F, Gravina A, Panico M, Bazzicalupo L, Salvatore M
Tc-99m MIBI scintigraphy in patients with lung cancer comparison with CT and fluorine-18 FDG PET imaging (623 views)
Clin Nucl Med (ISSN: 0363-9762, 1536-0229, 1536-0229electronic), 1997 Apr; 22(4): 243-249.
Impact Factor: 0.34
View Export to BibTeX Export to EndNote
9 Records (8 excluding Abstracts).
Total impact factor: 36.655 (34.247 excluding Abstracts).
Total 5 year impact factor: 40.658 (38.2 excluding Abstracts).
Total impact factor: 36.655 (34.247 excluding Abstracts).
Total 5 year impact factor: 40.658 (38.2 excluding Abstracts).
623 views. Last view on Monday 07 April 2025, 16:54:59
ibb.cnr.it
